Research Progress of Acquired Resistance Mediated by MET Amplification
in Advanced Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2022.102.23
- Author:
Sisi PAN
1
;
Na WANG
1
;
Xia SONG
2
Author Information
1. The Second Clinical Medical College of Shanxi Medical University, Taiyuan 030001, China.
2. The Second Department of Respiratory, Shanxi Provincial Cancer Hospital, Taiyuan 030013, China.
- Publication Type:Review
- Keywords:
Acquired resistance;
Lung neoplasms;
MET amplification;
Targeted therapy
- MeSH:
Carcinoma, Non-Small-Cell Lung/genetics*;
Drug Resistance, Neoplasm/genetics*;
ErbB Receptors/genetics*;
Humans;
Lung Neoplasms/pathology*;
Mutation;
Protein Kinase Inhibitors/therapeutic use*;
Protein-Tyrosine Kinases;
Proto-Oncogene Proteins/genetics*;
Proto-Oncogene Proteins c-met/genetics*
- From:
Chinese Journal of Lung Cancer
2022;25(8):615-621
- CountryChina
- Language:Chinese
-
Abstract:
Mesenchymal-epithelial transition factor (MET) amplification is an important driver of resistance in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and the combination of MET proto-oncogene (MET) and EGFR-tyrosine kinase inhibitors (TKIs) has shown promise in overcoming this molecularly defined acquired resistance. Emerging data also demonstrate MET amplification as a resistance driver to TKIs-treated anaplastic lymphoma kinase (ALK)-, RET-, and ROS1-fusion NSCLC. Here, we review the literature on recent research progress of MET amplification as a resistance driver to targeted therapy in oncogene-driven NSCLC and summarize the progress of clinical strategies to overcome the resistance mechanism.
.
